Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
Rhea-AI Summary
Eledon Pharmaceuticals (Nasdaq: ELDN) will participate in the Leerink Partners 2026 Global Healthcare Conference.
Chief Executive Officer David-Alexandre C. Gros, M.D. and President & Chief Scientific Officer Steven Perrin, Ph.D. will appear in a fireside chat on March 11, 2026 at 1:40 p.m. ET. A live webcast requires advance registration and a replay will be posted under Events on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – ELDN
On the day this news was published, ELDN gained 4.38%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.3% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $204M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ELDN fell 6.02% while close biotech peers were mixed: gains in MCRB (+1.03%) and CABA (+1.56%) contrasted with declines in NKTX (-3.02%), AARD (-9.33%), and NVCT (-2.02%), indicating stock-specific pressure rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Conference participation | Neutral | +11.2% | Announced fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026. |
| Jan 23 | Clinical data update | Positive | -4.0% | Reported 24‑month Phase 1b extension data in de novo kidney transplant patients. |
| Jan 08 | Business outlook & financing | Positive | +0.0% | Summarized 2025 milestones, Phase 2 BESTOW data, and $57.5M financing with 2026 outlook. |
| Dec 01 | Conference participation | Neutral | -6.1% | Announced CEO fireside chat at 37th Annual Piper Sandler Healthcare Conference. |
| Nov 18 | Clinical data update | Positive | +0.7% | Shared preliminary islet transplant data showing insulin independence in six T1D patients. |
Recent ELDN news has shown mixed alignment with price: positive clinical and corporate updates sometimes saw negative or flat reactions, while neutral conference participation headlines have coincided with both sharp gains and declines, suggesting event-driven volatility without a consistent pattern.
Over the last several months, Eledon has combined conference visibility with advancing tegoprubart. Clinical readouts in kidney transplantation and type 1 diabetes (e.g., long-term Phase 1b data and investigator-initiated islet transplant results) reported favorable efficacy and safety. A January 2026 business update highlighted Phase 2 BESTOW outcomes, xenotransplant experience, and a $57.5 million financing expected to fund operations into 2Q 2027. Alongside these, multiple conference appearances, like Guggenheim and Piper Sandler, emphasize ongoing investor outreach, similar in nature to today’s Leerink participation news.
Market Pulse Summary
This announcement highlights Eledon’s continued engagement with the investment community via a Leerink Partners fireside chat on March 11, 2026. It follows a series of clinical updates on tegoprubart and a $57.5 million financing expected to fund operations into 2Q 2027. Investors may focus on any incremental commentary about Phase 3 planning, long-term safety and efficacy data, and future capital needs, given the company’s recent trial activity and regulatory filings.
AI-generated analysis. Not financial advice.
IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the upcoming Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET (10:40 a.m. PT).
To register in advance for the fireside chat webcast, sign up here.
A webcast replay will be accessible following the live session on the Company’s website under Events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
FAQ
When will Eledon (ELDN) present at the Leerink Partners 2026 Global Healthcare Conference?
Who from Eledon (ELDN) will speak at the March 11, 2026 fireside chat?
How can investors watch the Eledon (ELDN) webinar at the Leerink 2026 conference?
Will a replay of Eledon’s (ELDN) Leerink 2026 fireside chat be available after the live event?
What time is Eledon’s (ELDN) fireside chat in Pacific Time on March 11, 2026?
